Phase II trial of the combination of transurethral resection and neoadjuvant chemotherapy [methotrexate + vinblastine + doxorubicin + cisplatin] for patients with invasive urothelial tract tumors selected by stage and p53 nuclear expression
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Doxorubicin; Granulocyte colony-stimulating factors; Methotrexate; Vinblastine
- Indications Bladder cancer
- Focus Therapeutic Use
- 03 Jul 2013 Biomarkers information updated
- 17 Dec 2009 Actual end date (1 Jan 2003) added as reported by ClinicalTrials.gov record.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov